Market Overview:
The global adrenocortical carcinoma drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of adrenocortical carcinoma, rising awareness about the disease, and technological advancements in the field of cancer treatment. The global adrenocortical carcinoma drugs market is segmented on the basis of type into chemotherapy and targeted therapy. On the basis of application, it is segmented into hospital, research institute, clinic, and other segments. Geographically, it is segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
Adrenocortical carcinoma drugs are used to treat adrenocortical carcinoma, a rare cancer that begins in the outer layer of the adrenal gland. Adrenocortical carcinomas often produce high levels of hormones, which can cause symptoms such as headaches, anxiety, and excessive sweating. Drugs that reduce hormone production may be used to control these symptoms.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy includes a group of medical procedures used to reduce, control, or prevent cancer. The most common types of chemotherapies include alkylating agents (such as busulfan), cytotoxic agents (such as carmustine), antimetabolites (such as 5-fluorouracil), and plant derivatives (toxins such as taxotere).
Targeted therapy:
Targeted therapy is a type of chemotherapy which is used to treat cancer. It works by targeting only the bad cells and leaving the good ones unaffected. This makes it an effective treatment for cancer as compared to traditional chemotherapy, which attacks all cells in the body.
U.S Targeted Therapy Market Share, By Drug Class (Adrenocortical Carcinoma), 2018 - 2025 -> The U.
Application Insights:
The hospital application segment dominated the global adrenocortical carcinoma drugs market in 2017. The high prevalence of cancer and increasing awareness about treatment options are some of the factors responsible for this segment¢â‚¬â„¢s dominance. For instance, according to data published by WHO in 2018, around 1 million people die from cancer every year worldwide. Moreover, as per that same source, around 5-10% patients suffering from non-metastatic prostate cancer are candidates for surgical removal of the tumor which can be treated with minimally invasive procedures such as robotic surgery or laparoscopic techniques. These facts provide a strong case for hospitals to adopt an aggressive approach towards diagnosing and treating ADCCT thus supporting its hospital application segment growth during the forecast period.
The other applications segment includes clinics.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research & development activities, and high healthcare expenditure in this region. Moreover, increasing cases of cancer are also contributing towards growth. For instance, as per statistics published by American Cancer Society in 2018 around 1 million new cases were estimated to be diagnosed in U.S., out of which about 925000 were prostate cancer and 250000 adrenal gland tumors (also known as primary malignant tumor).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income leading to an increase in demand for healthcare services resulting into higher spending on R&D activities by companies engaged in drug development for target diseases such as cancers and other immunological disorders among others that have a significant impact on overall economic performance of countries worldwide including China & India thereby driving regional market growth during the forecast period from 2018 To 2030 (Ref: World Bank Group).
Growth Factors:
- Increasing incidence of adrenocortical carcinoma
- Growing demand for better treatment options for adrenocortical carcinoma
- Rising awareness about the availability of advanced treatment options for adrenocortical carcinoma
- Technological advancements in the field of diagnosis and treatment of adrenocortical carcinoma
- increasing research and development investments in the field of adrenocortical carcinoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Adrenocortical Carcinoma Drugs Market Research Report
By Type
Chemotherapy, Targeted therapy
By Application
Hospital, Research institute, Clinic, Other
By Companies
Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Adrenocortical Carcinoma Drugs Market Report Segments:
The global Adrenocortical Carcinoma Drugs market is segmented on the basis of:
Types
Chemotherapy, Targeted therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research institute, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Laboratoire HRA Pharma SAS
- Progenics Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Highlights of The Adrenocortical Carcinoma Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Targeted therapy
- By Application:
- Hospital
- Research institute
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Adrenocortical Carcinoma Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Adrenocortical carcinoma drugs are medications that are used to treat adrenocortical cancer. These drugs can help to shrink or stop the growth of the cancer, and may also help to improve the patient's overall health.
Some of the major players in the adrenocortical carcinoma drugs market are Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Adrenocortical Carcinoma Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Adrenocortical Carcinoma Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Adrenocortical Carcinoma Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Adrenocortical Carcinoma Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Adrenocortical Carcinoma Drugs Market Size & Forecast, 2018-2028
4.5.1 Adrenocortical Carcinoma Drugs Market Size and Y-o-Y Growth
4.5.2 Adrenocortical Carcinoma Drugs Market Absolute $ Opportunity
Chapter 5 Global Adrenocortical Carcinoma Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Adrenocortical Carcinoma Drugs Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Targeted therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Adrenocortical Carcinoma Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research institute
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Adrenocortical Carcinoma Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Adrenocortical Carcinoma Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Adrenocortical Carcinoma Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Adrenocortical Carcinoma Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Adrenocortical Carcinoma Drugs Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Targeted therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research institute
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Adrenocortical Carcinoma Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Adrenocortical Carcinoma Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Adrenocortical Carcinoma Drugs Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Targeted therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research institute
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Adrenocortical Carcinoma Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Adrenocortical Carcinoma Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Adrenocortical Carcinoma Drugs Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Targeted therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research institute
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Adrenocortical Carcinoma Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Adrenocortical Carcinoma Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Adrenocortical Carcinoma Drugs Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Targeted therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research institute
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Adrenocortical Carcinoma Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Adrenocortical Carcinoma Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Adrenocortical Carcinoma Drugs Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Targeted therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Adrenocortical Carcinoma Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research institute
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Adrenocortical Carcinoma Drugs Market: Competitive Dashboard
14.2 Global Adrenocortical Carcinoma Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb Co.
14.3.2 Eli Lilly and Co.
14.3.3 Laboratoire HRA Pharma SAS
14.3.4 Progenics Pharmaceuticals Inc.
14.3.5 Teva Pharmaceutical Industries Ltd.
